This morning, former CDC director Susan Monarez appeared before the Senate to discuss her termination by Health and Human Services Secretary Robert F. Kennedy Jr. and President Donald Trump. This incident highlights an ongoing clash between the Trump administration and public health officials.
Monarez testified that her dismissal was linked to the upcoming Advisory Committee on Immunization Practices (ACIP) meeting, scheduled for the next two days. During a tense conversation with Kennedy before her firing, she claims he pressured her to approve new vaccine recommendations without reviewing them. The committee now includes experts chosen by Kennedy, who also urged her to dismiss CDC vaccine scientists.
As she spoke to the Senate health committee, Monarez maintained her composure even as various Republican senators questioned her credibility. In contrast, the committee chair, Sen. Bill Cassidy (R-LA), a physician, warned against making unwarranted changes to childhood vaccine schedules, notably concerning the hepatitis B vaccine.
Tomorrow and Friday, the ACIP will evaluate potential alterations to the childhood vaccine schedule, alongside the federal guidance for COVID-19, hepatitis B, and measles-mumps-rubella vaccines. Changes to the guidance for hepatitis B shots, particularly, became a focal point during Wednesday’s hearing.
The rift over the hepatitis B vaccine, briefly explained
So, why is the hepatitis B vaccine suddenly so significant in this discussion? It has long been a target for anti-vaccine advocates, as it is administered shortly after birth. During the Senate hearing, some Republican senators seemed supportive of potential changes: Sen. Rand Paul (R-KY) suggested delaying the administration of this vaccine, arguing that it should only be given if the mother is known to carry hepatitis B.
By the end of the hearing, Cassidy pointed out the seriousness of hepatitis B in newborns, noting that without intervention, over 90 percent of infected infants develop chronic infections. He reminded attendees that before the hepatitis B vaccine became standard in the early 1990s, the US reported approximately 20,000 newborn infections annually — a number that has since plummeted to fewer than 20.
He stressed that this achievement is a testament to efforts in making America healthier and emphasized the importance of supporting those who made the vaccination decision, as many lives have been saved.
Cassidy clarified that the CDC does not mandate the hepatitis B vaccine; it merely requires insurance coverage if parents opt for it. He raised concerns about the potential fallout if the ACIP were to revoke the recommendation for newborn vaccination, mentioning that insurers might stop covering the cost.
While today’s testimony from the former CDC director didn’t lead to widespread calls for Kennedy’s resignation, mounting opposition to his ambitious vaccine policy changes has been evident.
Earlier this month, Sen. John Barrasso (R-WY) questioned Kennedy on vaccine effectiveness during a separate hearing. Reports suggest a growing uncertainty among other GOP lawmakers about Kennedy’s direction, although he continues to have a solid base of support; apart from Cassidy and Sen. Susan Collins (R-ME), most Republican inquiries directed at Monarez were critical.
Cassidy’s role is pivotal. As a respected physician and health committee chair, his stance on Kennedy’s agenda holds significant weight. If he decides to challenge Kennedy further, he has the power to investigate the health agency, seek more testimonies, and oppose policies on the Senate floor.
Now, Cassidy has nearly signaled a warning to both ACIP and Kennedy regarding unauthorized changes to the hepatitis B vaccination recommendations. Their next move will unfold in the coming days.
